Cost Analysis of Technetium-99m versus Indocyanine Green for Sentinel Lymph Node Biopsy in Breast Cancer
Clinical Breast Cancer · 2026
DOI: 10.1016/j.clbc.2025.12.005 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Iva M Borisova Boyanova und 8 weiteren Autor:innen. Beteiligte Einrichtung: General of Surgery Department, Fundación Hospitalarias Barcelona, Barcelona, Spain. Electronic address: iva.borisova@fundacionhospitalarias.org. Hauptthemen laut MEDLINE: Sentinel Lymph Node Biopsy, Indocyanine Green, Breast Neoplasms, Technetium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Asociación Española de Cirujanos.
Abstract (Originalsprache)
BACKGROUND: Sentinel lymph node biopsy (SLNB) using Technetium-99 (Tc-99) is the standard technique for axillary staging in breast cancer. However, it has logistic issues, especially in hospitals without a nuclear medicine department (NMD). As the sensitivity and specificity of indocyanine green (ICG) are comparable to those of Tc-99, the aim of this study was to perform a cost-benefit analysis of the 2 methods. MATERIALS AND METHODS: A prospective observational cohort of patients undergoing breast cancer surgery was included. Tc-99 and ICG were administered during the same procedure for SLNB. Three clinical pathways were constructed: Tc-99 administration at hospitals without NMD (first clinical pathway), Tc-99 administration at hospitals with NMD (second), and the ICG method (third). A cost comparison between the pathways was performed using the monetary unit of Euros (€). RESULTS: Between April 2021 and April 2024, 112 patients with breast cancer underwent SLNB using Tc-99 and ICG detection. The total cost per patient for the first clinical pathway was €322.29, for the second, €308.29 and for the third, €61.35 per patient. The cumulative cost for 112 patients in the first and second clinical pathways (€37,216.48 and €34,528.48, respectively) resulted to be 5.2 times the cost of the ICG pathway (€6871.2). The use of ICG results in an average saving of approximately 80% of the Tc-99 expenses. CONCLUSION: ICG is a cost-effective option as a tracer for sentinel lymph node biopsy in breast cancer. ICG also offers logistic advantages and it should be considered in clinical practice and protocols.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General of Surgery Department, Fundación Hospitalarias Barcelona, Barcelona, Spain. Electronic address: iva.borisova@fundacionhospitalarias.org.
- Department of Surgery, Universitat Autònoma de Barcelona, Barcelona, Spain; General of Surgery and Breast Surgery Department, Hospital Universitario Germans Trias i Pujol, Badalona, Spain.
- Surgical Nurse, General of Surgery Department, General Hospital, Madrid, Spain.
- General of Surgery and Breast Surgery Department, Consorcio Sanitario del Maresme, Hospital de Mataró, Mataró, Spain.
- Obstetrics and Gynecology Department, Consorcio Sanitario del Maresme, Hospital de Mataró, Mataró, Spain.
- Nuclear Medicine Department, Hospital Universitario Germans Trias i Pujol, Badalona, Spain.
Förderung
- Asociación Española de Cirujanos
Zitieren
APA
Borisova Boyanova, I. M., Blay Aulina, L., de la Iglésia, M., López-Cano, D., Serra-Serra, C., Ruiz-Edo, N., Salcedo-Pujantell, M., Julián Ibañéz, J., & López Gordo, S. (2026). Cost Analysis of Technetium-99m versus Indocyanine Green for Sentinel Lymph Node Biopsy in Breast Cancer. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.12.005
Vancouver
Borisova Boyanova IM, Blay Aulina L, de la Iglésia M, López-Cano D, Serra-Serra C, Ruiz-Edo N, et al. Cost Analysis of Technetium-99m versus Indocyanine Green for Sentinel Lymph Node Biopsy in Breast Cancer. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2025.12.005
BibTeX
@article{BorisovaBoyanova2026,
author = {Borisova Boyanova, Iva M and Blay Aulina, Lidia and de la Iglésia, Marta and López-Cano, David and Serra-Serra, Cristina and Ruiz-Edo, Neus and Salcedo-Pujantell, Maite and Julián Ibañéz, Juan and López Gordo, Sandra},
title = {Cost Analysis of Technetium-99m versus Indocyanine Green for Sentinel Lymph Node Biopsy in Breast Cancer},
journal = {Clinical Breast Cancer},
year = {2026},
doi = {10.1016/j.clbc.2025.12.005}
}
EUVIMED